These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7726505)

  • 1. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
    Fantin B; Leclercq R; Merlé Y; Saint-Julien L; Veyrat C; Duval J; Carbon C
    Antimicrob Agents Chemother; 1995 Feb; 39(2):400-5. PubMed ID: 7726505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 May; 44(5):1168-73. PubMed ID: 10770747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
    Fantin B; Leclercq R; Garry L; Carbon C
    Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.
    Pavie J; Lefort A; Zarrouk V; Chau F; Garry L; Leclercq R; Fantin B
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3061-4. PubMed ID: 12183272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
    Berthaud N; Huet Y; Diallo N; Desnottes JF
    J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.
    Vouillamoz J; Entenza JM; Féger C; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1789-95. PubMed ID: 10858332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
    Bozdogan B; Leclercq R
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
    Griswold MW; Lomaestro BM; Briceland LL
    Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection.
    Carbon C
    J Antimicrob Chemother; 1997 May; 39 Suppl A():115-9. PubMed ID: 9511075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
    Malbruny B; Canu A; Bozdogan B; Fantin B; Zarrouk V; Dutka-Malen S; Feger C; Leclercq R
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2200-7. PubMed ID: 12069975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
    Garcia R; Raad I
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):933-6. PubMed ID: 9031876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Rybak MJ; Houlihan HH; Mercier RC; Kaatz GW
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1359-63. PubMed ID: 9174199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.